Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Ionis Pharmaceuticals Inc (IONS)
since 2015 are shown in Table 1 and Table 2.
Table 1 shows the monthly insider trading data of Ionis Pharmaceuticals Inc.
(See page 1 of this report.) Table 2 shows the detailed insider transactions.
This company's CIK number is 874015.
Total stock buying since 2015: $477,900.
Total stock sales since 2015: $233,167,209.
Total stock option exercises since 2015: $94,799,909.
Table 3. Detailed insider trading at Ionis Pharmaceuticals Inc (IONS) , Part 2
| Trade Date |
Insider Name |
Trade Type |
Shares |
Price ($) |
Value ($) |
| 2024-02-02 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 1,961 | 49.67 | 97,410 |
| 2024-02-02 | Monia Brett P (Chief Executive Officer) | Sale | 23,501 | 49.37 | 1,160,314 |
| 2024-02-02 | Geary Richard S (EVP, Chief Development Officer) | Sale | 1,961 | 50.04 | 98,134 |
| 2024-02-02 | Hougen Elizabeth L (EVP, Finance & CFO) | Sale | 2,125 | 49.54 | 105,272 |
| 2024-02-02 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 1,853 | 49.52 | 91,753 |
| 2024-01-31 | Swayze Eric (EVP Research) | Sale | 10,773 | 52.00 | 560,196 |
| 2024-01-25 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 6,450 | 51.75 | 333,787 |
| 2024-01-25 | Monia Brett P (Chief Executive Officer) | Sale | 2,285 | 51.75 | 118,248 |
| 2024-01-17 | Birchler Brian (EVP, Corp and Development Ops) | Sale | 4,497 | 50.42 | 226,725 |
| 2024-01-17 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 5,482 | 50.42 | 276,385 |
| 2024-01-17 | Baroldi Joseph (EVP, Chief Business Officer) | Sale | 2,024 | 50.42 | 102,044 |
| 2024-01-17 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Sale | 5,564 | 50.42 | 280,520 |
| 2024-01-17 | Swayze Eric (EVP Research) | Sale | 6,305 | 50.42 | 317,879 |
| 2024-01-17 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 7,744 | 50.42 | 390,429 |
| 2024-01-17 | Monia Brett P (Chief Executive Officer) | Sale | 32,059 | 50.42 | 1,616,318 |
| 2024-01-17 | Geary Richard S (EVP, Chief Development Officer) | Sale | 7,338 | 50.42 | 369,959 |
| 2024-01-17 | Hougen Elizabeth L (EVP, Finance & CFO) | Sale | 8,683 | 50.42 | 437,770 |
| 2024-01-17 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 6,745 | 50.42 | 340,062 |
| 2024-01-16 | Birchler Brian (EVP, Corp and Development Ops) | Option Ex | 12,080 | .00 | 0 |
| 2024-01-16 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 15,162 | .00 | 0 |
| 2024-01-16 | Baroldi Joseph (EVP, Chief Business Officer) | Option Ex | 5,041 | .00 | 0 |
| 2024-01-16 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Option Ex | 15,062 | .00 | 0 |
| 2024-01-16 | Swayze Eric (EVP Research) | Option Ex | 17,090 | .00 | 0 |
| 2024-01-16 | O'neil Patrick R. (EVP CLO & General Counsel) | Option Ex | 20,641 | .00 | 0 |
| 2024-01-16 | Monia Brett P (Chief Executive Officer) | Option Ex | 68,084 | .00 | 0 |
| 2024-01-16 | Geary Richard S (EVP, Chief Development Officer) | Option Ex | 19,852 | .00 | 0 |
| 2024-01-16 | Hougen Elizabeth L (EVP, Finance & CFO) | Option Ex | 22,487 | .00 | 0 |
| 2024-01-16 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 18,314 | .00 | 0 |
| 2024-01-12 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 8,000 | 53.50 | 428,000 |
| 2024-01-12 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 8,000 | 32.60 | 260,800 |
| 2023-12-28 | Birchler Brian (EVP, Corp and Development Ops) | Option Ex | 11,500 | 47.34 | 544,410 |
| 2023-12-28 | Swayze Eric (EVP Research) | Sale | 27,100 | 50.19 | 1,360,094 |
| 2023-12-28 | Swayze Eric (EVP Research) | Option Ex | 27,100 | 47.34 | 1,282,914 |
| 2023-12-28 | Hougen Elizabeth L (EVP, Finance & CFO) | Option Ex | 45,225 | 47.34 | 2,140,951 |
| 2023-12-28 | Parshall B Lynne (Director) | Sale | 42,525 | 50.19 | 2,134,244 |
| 2023-12-28 | Parshall B Lynne (Director) | Option Ex | 42,525 | 47.34 | 2,013,133 |
| 2023-12-27 | Parshall B Lynne (Director) | Sale | 50,000 | 50.23 | 2,511,500 |
| 2023-12-27 | Parshall B Lynne (Director) | Option Ex | 50,000 | 47.34 | 2,367,000 |
| 2023-12-26 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 25,000 | 51.46 | 1,286,575 |
| 2023-12-26 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 25,000 | 47.34 | 1,183,500 |
| 2023-12-26 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 20,825 | 51.46 | 1,071,716 |
| 2023-12-26 | O'neil Patrick R. (EVP CLO & General Counsel) | Option Ex | 20,825 | 47.34 | 985,855 |
| 2023-12-26 | Parshall B Lynne (Director) | Sale | 25,113 | 51.46 | 1,292,390 |
| 2023-12-26 | Parshall B Lynne (Director) | Option Ex | 25,113 | 47.34 | 1,188,849 |
| 2023-12-21 | Monia Brett P (Chief Executive Officer) | Sale | 17,500 | 49.29 | 862,575 |
| 2023-12-21 | Monia Brett P (Chief Executive Officer) | Option Ex | 17,500 | 47.34 | 828,450 |
| 2023-12-21 | Geary Richard S (EVP, Chief Development Officer) | Sale | 4,112 | 49.29 | 202,680 |
| 2023-12-21 | Geary Richard S (EVP, Chief Development Officer) | Option Ex | 4,112 | 47.34 | 194,662 |
| 2023-12-21 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 16,113 | 49.29 | 794,209 |
| 2023-12-21 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 16,113 | 47.34 | 762,789 |
| 2023-12-20 | Monia Brett P (Chief Executive Officer) | Sale | 6,500 | 49.64 | 322,640 |
| 2023-12-20 | Monia Brett P (Chief Executive Officer) | Option Ex | 6,500 | 47.34 | 307,710 |
| 2023-12-20 | Geary Richard S (EVP, Chief Development Officer) | Sale | 6,500 | 49.64 | 322,640 |
| 2023-12-20 | Geary Richard S (EVP, Chief Development Officer) | Option Ex | 6,500 | 47.34 | 307,710 |
| 2023-12-20 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 6,500 | 49.64 | 322,640 |
| 2023-12-20 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 6,500 | 47.34 | 307,710 |
| 2023-12-14 | Monia Brett P (Chief Executive Officer) | Sale | 24,000 | 49.70 | 1,192,800 |
| 2023-12-14 | Monia Brett P (Chief Executive Officer) | Option Ex | 24,000 | 47.34 | 1,136,160 |
| 2023-12-14 | Geary Richard S (EVP, Chief Development Officer) | Sale | 10,613 | 49.70 | 527,466 |
| 2023-12-14 | Geary Richard S (EVP, Chief Development Officer) | Option Ex | 10,613 | 47.34 | 502,419 |
| 2023-12-14 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 22,612 | 49.70 | 1,123,816 |
| 2023-12-14 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 22,612 | 47.34 | 1,070,452 |
| 2023-10-17 | Swayze Eric (EVP Research) | Sale | 52 | 47.95 | 2,493 |
| 2023-10-16 | Swayze Eric (EVP Research) | Option Ex | 125 | .00 | 0 |
| 2023-10-12 | Monia Brett P (Chief Executive Officer) | Sale | 3,770 | 46.00 | 173,420 |
| 2023-09-28 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 4,460 | 46.50 | 207,390 |
| 2023-09-26 | Klein Joseph Iii (Director) | Sale | 2,000 | 45.13 | 90,254 |
| 2023-09-26 | Parshall B Lynne (Director) | Sale | 10,000 | 45.13 | 451,270 |
| 2023-08-01 | Diaz Allene M. (Director) | Sale | 657 | 41.05 | 26,969 |
| 2023-07-18 | Klein Joseph Iii (Director) | Sale | 3,555 | 42.00 | 149,310 |
| 2023-07-17 | Diaz Allene M. (Director) | Option Ex | 5,333 | .00 | 0 |
| 2023-07-17 | Hayden Michael R (Director) | Option Ex | 7,110 | .00 | 0 |
| 2023-07-17 | Loscalzo Joseph (Director) | Option Ex | 7,110 | .00 | 0 |
| 2023-07-17 | Herman Joan E (Director) | Option Ex | 7,110 | .00 | 0 |
| 2023-07-17 | Klein Joseph Iii (Director) | Option Ex | 7,110 | .00 | 0 |
| 2023-07-17 | Berthelsen Spencer R (Director) | Option Ex | 7,110 | .00 | 0 |
| 2023-07-17 | Parshall B Lynne (Director) | Option Ex | 7,110 | .00 | 0 |
| 2023-07-17 | Wender Joseph H (Director) | Option Ex | 7,110 | .00 | 0 |
| 2023-07-07 | Monia Brett P (Chief Executive Officer) | Sale | 18,650 | 42.25 | 787,962 |
| 2023-06-20 | Berthelsen Spencer R (Director) | Option Ex | 11,250 | 28.47 | 320,287 |
| 2023-06-12 | Herman Joan E (Director) | Option Ex | 3,555 | .00 | 0 |
| 2023-05-24 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 1,527 | 41.70 | 63,675 |
| 2023-05-22 | Monia Brett P (Chief Executive Officer) | Sale | 4,931 | 40.13 | 197,905 |
| 2023-04-18 | Birchler Brian (EVP, Corp and Development Ops) | Sale | 672 | 36.50 | 24,529 |
| 2023-04-18 | Baroldi Joseph (EVP, Chief Business Officer) | Sale | 3,880 | 36.50 | 141,631 |
| 2023-04-18 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Sale | 2,582 | 36.50 | 94,250 |
| 2023-04-17 | Birchler Brian (EVP, Corp and Development Ops) | Option Ex | 1,875 | .00 | 0 |
| 2023-04-17 | Baroldi Joseph (EVP, Chief Business Officer) | Option Ex | 10,838 | .00 | 0 |
| 2023-04-17 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Option Ex | 5,667 | .00 | 0 |
| 2023-02-06 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 1,413 | 40.67 | 57,463 |
| 2023-02-06 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Sale | 1,451 | 40.66 | 58,997 |
| 2023-02-06 | Swayze Eric (EVP Research) | Sale | 1,815 | 40.79 | 74,032 |
| 2023-02-06 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 1,920 | 40.87 | 78,460 |
| 2023-02-06 | Monia Brett P (Chief Executive Officer) | Sale | 24,651 | 40.69 | 1,003,147 |
| 2023-02-06 | Geary Richard S (EVP, Chief Development Officer) | Sale | 1,920 | 40.66 | 78,071 |
| 2023-02-06 | Hougen Elizabeth L (EVP, Finance & CFO) | Sale | 2,079 | 40.59 | 84,392 |
| 2023-02-06 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 1,813 | 40.57 | 73,560 |
| 2023-01-31 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 4,500 | 39.71 | 178,699 |
| 2023-01-30 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 4,500 | 39.42 | 177,372 |
| 2023-01-18 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Sale | 4,752 | 39.57 | 188,050 |
| 2023-01-18 | Baroldi Joseph (EVP, Chief Business Officer) | Sale | 375 | 39.79 | 14,920 |
| 2023-01-18 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Sale | 3,748 | 39.55 | 148,222 |
| 2023-01-18 | Swayze Eric (EVP Research) | Sale | 5,631 | 39.74 | 223,798 |
| 2023-01-18 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 7,836 | 39.49 | 309,482 |
| 2023-01-18 | Monia Brett P (Chief Executive Officer) | Sale | 25,066 | 39.49 | 989,956 |
| 2023-01-18 | Geary Richard S (EVP, Chief Development Officer) | Sale | 7,873 | 39.57 | 311,526 |
| 2023-01-18 | Hougen Elizabeth L (EVP, Finance & CFO) | Sale | 8,280 | 39.70 | 328,724 |
| 2023-01-18 | Bennett C Frank (EVP, Chief Scientific Officer) | Sale | 6,978 | 38.89 | 271,353 |
| 2023-01-17 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 13,046 | .00 | 0 |
| 2023-01-17 | Baroldi Joseph (EVP, Chief Business Officer) | Option Ex | 904 | .00 | 0 |
| 2023-01-17 | Cadoret-manier Onaiza (EVP, Chf GL Pdt Str & Oper Ofc) | Option Ex | 10,197 | .00 | 0 |
| 2023-01-17 | Swayze Eric (EVP Research) | Option Ex | 15,780 | .00 | 0 |
| 2023-01-17 | O'neil Patrick R. (EVP CLO & General Counsel) | Option Ex | 21,871 | .00 | 0 |
| 2023-01-17 | Monia Brett P (Chief Executive Officer) | Option Ex | 57,267 | .00 | 0 |
| 2023-01-17 | Geary Richard S (EVP, Chief Development Officer) | Option Ex | 21,983 | .00 | 0 |
| 2023-01-17 | Klein Joseph Iii (Director) | Sale | 2,000 | 40.00 | 80,000 |
| 2023-01-17 | Hougen Elizabeth L (EVP, Finance & CFO) | Option Ex | 23,154 | .00 | 0 |
| 2023-01-17 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 19,417 | .00 | 0 |
| 2022-10-17 | Schneider Eugene (EVP, Chf Clinical Develop Ofcr) | Option Ex | 416 | .00 | 0 |
| 2022-10-17 | Hayden Michael R (Director) | Option Ex | 1,777 | .00 | 0 |
| 2022-09-08 | Swayze Eric (EVP Research) | Sale | 460 | 44.55 | 20,493 |
| 2022-08-05 | Swayze Eric (EVP Research) | Sale | 1 | 45.20 | 45 |
| 2022-07-15 | Diaz Allene M. (Director) | Option Ex | 8,000 | .00 | 0 |
| 2022-07-15 | Hayden Michael R (Director) | Option Ex | 7,110 | .00 | 0 |
| 2022-07-15 | Loscalzo Joseph (Director) | Option Ex | 7,998 | .00 | 0 |
| 2022-07-15 | Herman Joan E (Director) | Option Ex | 7,110 | .00 | 0 |
| 2022-07-15 | Klein Joseph Iii (Director) | Sale | 1,333 | 38.26 | 51,000 |
| 2022-07-15 | Klein Joseph Iii (Director) | Option Ex | 7,998 | .00 | 0 |
| 2022-07-15 | Muto Frederick T (Director) | Option Ex | 7,998 | .00 | 0 |
| 2022-07-15 | Berthelsen Spencer R (Director) | Option Ex | 7,998 | .00 | 0 |
| 2022-07-15 | Parshall B Lynne (Director) | Option Ex | 7,998 | .00 | 0 |
| 2022-07-15 | Wender Joseph H (Director) | Option Ex | 7,998 | .00 | 0 |
| 2022-07-01 | Muto Frederick T (Director) | Option Ex | 11,250 | 12.94 | 145,575 |
| 2022-06-10 | Herman Joan E (Director) | Option Ex | 3,555 | .00 | 0 |
| 2022-06-07 | Berthelsen Spencer R (Director) | Option Ex | 11,250 | 12.94 | 145,575 |
| 2022-04-21 | Swayze Eric (EVP Research) | Sale | 378 | 44.15 | 16,688 |
| 2022-04-18 | Cadoret-manier Onaiza (EVP, Chf Pdt Str & Oper Ofc) | Option Ex | 5,667 | .00 | 0 |
| 2022-04-12 | O'neil Patrick R. (EVP CLO & General Counsel) | Sale | 6,792 | 40.06 | 272,060 |
| 2022-04-01 | Monia Brett P (Chief Executive Officer) | Sale | 355 | 37.49 | 13,308 |
| 2022-01-18 | Schneider Eugene (EVP, Chf Clinical Develop Offc) | Option Ex | 10,400 | .00 | 0 |
| 2022-01-18 | Cadoret-manier Onaiza (EVP, Chf Corp Dev and Cml Offc) | Option Ex | 6,057 | .00 | 0 |
| 2022-01-18 | Swayze Eric (EVP Research) | Option Ex | 13,809 | .00 | 0 |
| 2022-01-18 | O'neil Patrick R. (EVP CLO & General Counsel) | Option Ex | 21,086 | .00 | 0 |
| 2022-01-18 | Monia Brett P (Chief Executive Officer) | Option Ex | 49,475 | .00 | 0 |
| 2022-01-18 | Geary Richard S (EVP, Chief Development Officer) | Option Ex | 21,391 | .00 | 0 |
| 2022-01-18 | Hougen Elizabeth L (EVP, Finance & CFO) | Option Ex | 22,050 | .00 | 0 |
| 2022-01-18 | Bennett C Frank (EVP, Chief Scientific Officer) | Option Ex | 18,842 | .00 | 0 |
| 2022-01-18 | Parshall B Lynne (Director) | Option Ex | 5,754 | .00 | 0 |
| 2021-10-15 | Schneider Eugene (EVP, Chf Clinical Develop Offc) | Option Ex | 417 | .00 | 0 |
| 2021-10-15 | Reikes Peter N (Director) | Option Ex | 1,777 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
of IONS listed in the above tables cannot be completely guaranteed as to their accuracy.
For more insider trading information of Ionis Pharmaceuticals Inc (symbol IONS,
CIK number 874015) see
the Securities and Exchange Commission (SEC) website.